{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:44:05Z","timestamp":1792079045555,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.modpat.2026.101069","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:37:40Z","timestamp":1787614660000},"page":"101069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-treatment Nephrectomy"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-0495","authenticated-orcid":false,"given":"Payal","family":"Kapur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jarmale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Tahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Rakheja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satwik","family":"Rajaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.modpat.2026.101069_bib1","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101069_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.modpat.2026.101069_bib3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101069_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2021.06.009","article-title":"Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy?","volume":"80","author":"M\u00e9jean","year":"2021","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.modpat.2026.101069_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.modpat.2026.101069_bib6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2026.101069_bib7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101069_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.modpat.2026.101069_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.modpat.2026.101069_bib10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.modpat.2026.101069_bib11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.urolonc.2019.08.012","article-title":"Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma","volume":"37","author":"Singla","year":"2019","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101069_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.mpdhp.2024.02.002","article-title":"Best practices and recommendations for grossing and reporting of post-immunotherapy nephrectomy specimens: a single-institution experience of 70 cases","volume":"30","author":"Hwang","year":"2024","journal-title":"Diagn Histopathol"},{"issue":"18","key":"10.1016\/j.modpat.2026.101069_bib13","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.modpat.2026.101069_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14359","article-title":"How accurate is radiological imaging for perirenal fat and renal vein invasion in renal cell carcinoma?","volume":"75","author":"Ucer","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"8014","key":"10.1016\/j.modpat.2026.101069_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.modpat.2026.101069_bib16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.modpat.2026.101069_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/jnci\/djaf060","article-title":"Determinants of late metastases in renal cell carcinoma","volume":"117","author":"Kapur","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.modpat.2026.101069_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41746-025-01686-z","article-title":"Iterative refinement and goal articulation to optimize large language models for clinical information extraction","volume":"8","author":"Hein","year":"2025","journal-title":"NPJ Digit Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101069_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54769-y","article-title":"GrandQC: a comprehensive solution to quality control problem in digital pathology","volume":"15","author":"Weng","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.modpat.2026.101069_bib20","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1158\/0008-5472.CAN-21-2318","article-title":"Intratumoral resolution of driver gene mutation heterogeneity in renal cancer using deep learning","volume":"82","author":"Acosta","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.101069_bib21","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41467-025-57717-6","article-title":"Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial","volume":"16","author":"Jasti","year":"2025","journal-title":"Nat Commun"},{"issue":"Suppl 2","key":"10.1016\/j.modpat.2026.101069_bib22","article-title":"61: predicting immunotherapy response in ccRCC using deep learning on histopathological slides","volume":"30","author":"Rajaram","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.modpat.2026.101069_bib23","article-title":"A visually interpretable histopathology-based immune model predicts T-effector biology and response to immune checkpoint inhibition in clear cell renal cell carcinoma clinical trial and contemporary real-world datasets","author":"Perny","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.modpat.2026.101069_bib24","first-page":"61","article-title":"HoVer-NeXt: a fast nuclei segmentation and classification pipeline for next generation histopathology","volume":"250","author":"Baumann","year":"2024","journal-title":"Proc Mach Learn Res"},{"key":"10.1016\/j.modpat.2026.101069_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.annonc.2025.05.540","article-title":"What is required to deliver practice\u2014changing neoadjuvant trials in kidney cancer? An International Neoadjuvant Kidney Cancer Consortium Delphi study","volume":"36","author":"Rossi","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101069_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2026.101069_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7 neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"issue":"6 suppl","key":"10.1016\/j.modpat.2026.101069_bib28","volume":"39","author":"Powles","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101069_bib29","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.modpat.2026.101069_bib30","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","article-title":"Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)","volume":"29","author":"Cottrell","year":"2018","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.modpat.2026.101069_bib31","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101069_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.euo.2025.11.003","article-title":"Pathologic response to immunotherapy is associated with survival in patients undergoing delayed nephrectomy for metastatic renal cell carcinoma","volume":"9","author":"Khandwala","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101069_bib33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","article-title":"Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma","volume":"27","author":"Cheville","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101069_bib34","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cncr.21206","article-title":"Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness","volume":"104","author":"Sengupta","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.modpat.2026.101069_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/his.13737","article-title":"Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization\/International Society of Urological Pathology grading for clear cell renal cell carcinoma","volume":"74","author":"Dagher","year":"2019","journal-title":"Histopathology"},{"issue":"10","key":"10.1016\/j.modpat.2026.101069_bib36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/PAS.0b013e318299f0fb","article-title":"The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101069_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/PAS.0b013e318270f71c","article-title":"A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis","volume":"37","author":"Delahunt","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2026.101069_bib38","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/PAS.0000000000000690","article-title":"Tumor necrosis adds prognostically significant information to grade in clear cell renal cell carcinoma: a study of 842 consecutive cases from a single institution","volume":"40","author":"Khor","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101069_bib39","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.juro.2008.11.098","article-title":"Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence\/absence classification","volume":"181","author":"Klatte","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.modpat.2026.101069_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.humpath.2017.06.010","article-title":"Prognostic significance of extensive necrosis in renal cell carcinoma","volume":"66","author":"Collins","year":"2017","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.101069_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.101069_bib42","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.101069_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:46:38Z","timestamp":1792075598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0893395226001122"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101069","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-treatment Nephrectomy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101069"}}